You can have a perfectly designed protocol, a well-resourced site, and a strong PI. None of it matters if you can't answer both.
Most patients who would qualify for a trial never hear about it. The pipeline problem isn't just a recruitment inefficiency — it's a structural failure in how trials reach eligible individuals.
Finding patients is hard. Keeping them is harder. Between visits, participants have no meaningful connection to the trial — and that silence compounds into dropout.
Most clinical trial platforms treat the participant experience as an afterthought — "here's a portal, log in and take the survey." Flusso built the participant experience first, then built the researcher tools to configure what participants would see. That's why the expected outcomes are so different.

You configure everything your trial needs in a single dashboard:
Everything you configure becomes live the moment you publish. No backend work. No delays.
Participants experience your trial through the app they already trust — the one they use for GP messages, appointment reminders, and health coordination. They see:
Participants never need to download a new app. They never need to remember a new login. Your trial lives in the app they're already using.

Flusso includes full clinical trial management — protocol design, visit scheduling, ePRO surveys, site coordination, audit trails, and ICH E6(R3) compliance. It's a working CTMS. But it also does things your current tools can't.
Enterprise platforms like Veeva and Medidata have deep trial operations — eTMF, RTSM, drug supply. But participant-facing capabilities are separate products with separate data models. On Flusso, everything you configure is delivered directly to participants through Engage. One system, one data model.
Site tools like CRIO and RealTime add recruitment campaigns, SMS blasts, and lead tracking. These improve outreach efficiency — but they're still pushing messages through channels patients don't routinely check. Flusso sustains engagement because the trial fits into the app participants use for their everyday healthcare.
Standalone trial apps require a new download and a new relationship for every study. Engagement decays because patients have no reason to use the app outside of one trial. Engage handles trial activities and everyday healthcare — so it stays on the home screen long after a single study ends.
No CTMS competitor offers cross-organisation data governance. Data Coalitions let organisations agree to sharing norms once — every subsequent request is auto-validated. Data stays in source systems. Only governance norms travel. Your legal team approves sharing they'd never greenlight elsewhere.
Director of Cancer Research Operations, Monash University. Co-author, Australian Clinical Trials Handbook. Founding Director, Australian Clinical Trials Alliance. Clinical operations credibility at the founding level.
Privacy-preserving ML and AI governance. Former Head of Operations at OpenMined. Built Flusso's Contextual Integrity architecture from peer-reviewed foundations.
20+ years enterprise sales across APAC and Japan. Former Group VP at Verizon Business. Understands how complex technology decisions get made inside large organisations.
Helen Nissenbaum, Cornell Tech. 20 years of peer-reviewed research. 5,000+ academic citations. Flusso is the production implementation of this framework — not an interpretation of it.
Global execution partner, an elite team of experienced global industry execs and veteran strategic and financial advisors. Just under a dozen partners with multi-decade and multi-tech-sector experience.
We're actively seeking research organisations willing to run a study on the platform and help us validate with real data. We don't have published metrics yet. What we have is a platform built on sound architecture, shaped by clinical operations experience, and ready to demonstrate its value in practice.
Schedule a 30-minute discovery call. We'll show you the platform configured for your use case — not a generic demo.
Find patients. Keep them engaged. One integrated platform.